anti-CTLA4 antibody
Showing 1 - 25 of >10,000
Cervical Cancer Trial in Amsterdam (Anti-PD-1 antibody balstilimab)
Not yet recruiting
- Cervical Cancer
- Anti-PD-1 antibody balstilimab
-
Amsterdam, NetherlandsAmsterdam UMC
Oct 17, 2023
NSCLC Trial in Saint Petersburg, Cremona, Vilnius (REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab)
Terminated
- Non-small Cell Lung Cancer
- REGN2810/ipi
- +2 more
-
Saint Petersburg, Florida
- +2 more
Oct 22, 2022
Head and Neck Squamous Cell Carcinoma (HNSCC) Trial in Pittsburgh (Nivolumab, Relatlimab, Ipilimumab)
Recruiting
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Nivolumab
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Mar 31, 2022
Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))
Active, not recruiting
- Colorectal Cancer
- IBI310 (anti-CTLA-4 antibody)
- Sintilimab(anti-PD-1 antibody)
-
Beijing, ChinaBeijing cancer hospital
Sep 15, 2022
Synovial Sarcoma Trial in New York (ipilimumab)
Terminated
- Synovial Sarcoma
- ipilimumab
-
New York, New YorkMemorial Sloan-Kettering Cancer Center
Jun 23, 2021
Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma Trial in United States (Durvalumab, Tremelimumab)
Completed
- Endometrial Cancer
- +4 more
-
Basking Ridge, New Jersey
- +6 more
Jan 3, 2023
Hepatocellular Carcinoma Trial in Beijing (AK104, Lenvatinib)
Recruiting
- Hepatocellular Carcinoma
- AK104
- Lenvatinib
-
Beijing, Beijing, ChinaChinese PLA General Hospital
Oct 17, 2022
Skin Health and Quality of Life in Patients Receiving
Not yet recruiting
- Lung Cancer
- +7 more
- EQ-5D-5L questionnaire
- +2 more
-
Roma, ItalyRoberto Iacovelli
May 17, 2023
Hepatocellular Carcinoma Trial in Hangzhou (AK104 lenvatinib, AK104)
Active, not recruiting
- Hepatocellular Carcinoma
- AK104 lenvatinib
- AK104
-
Hangzhou, Zhejiang, ChinaThe first affilited hospital zhejiang university school of medci
Oct 17, 2022
Urinary Bladder Tumors Trial in San Antonio (AGEN1884, AGEN2034, Cisplatin)
Active, not recruiting
- Urinary Bladder Neoplasms
- AGEN1884
- +3 more
-
San Antonio, TexasMays Cancer Center
Mar 11, 2022
SCLC,Extensive Stage Trial in Changchun (AK104 IV infusion;Chiauranib oral)
Not yet recruiting
- SCLC,Extensive Stage
- AK104 IV infusion;Chiauranib oral
-
Changchun, Jilin, ChinaJilin Province Cancer Hospital
Aug 16, 2022
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8
Active, not recruiting
- Anatomic Stage II Breast Cancer AJCC v8
- +16 more
- Durvalumab
- Tremelimumab
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Trial (SBRT, Cadonilimab)
Not yet recruiting
- Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- SBRT
- Cadonilimab
- (no location specified)
Feb 8, 2023
Locally Advanced Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland
Not yet recruiting
- Locally Advanced Thyroid Gland Anaplastic Carcinoma
- +2 more
-
Chicago, Illinois
- +1 more
Jul 7, 2022
Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases Trial in United States (Botensilimab, Balstilimab)
Recruiting
- Advanced Cancer
- +7 more
-
Scottsdale, Arizona
- +14 more
Sep 15, 2022
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 Trial in Atlanta
Not yet recruiting
- Castration-Sensitive Prostate Carcinoma
- +2 more
- Abiraterone
- +9 more
-
Atlanta, Georgia
- +1 more
Feb 8, 2023
Recurrent or Metastatic Cervical Cancer Trial in Changsha, Hangzhou (AK104, Bevacizumab, Paclitaxel)
Active, not recruiting
- Recurrent or Metastatic Cervical Cancer
- AK104
- +3 more
-
Changsha, Hunan, China
- +1 more
Mar 28, 2022
Advanced Solid Tumor Trial in Zhengzhou, Linyi (BAT4706 Injection, BAT1308 Injection)
Not yet recruiting
- Advanced Solid Tumor
- BAT4706 Injection
- BAT1308 Injection
-
Zhengzhou, Henan, China
- +2 more
Nov 14, 2023
Breast Cancer, Head Neck Cancer, Squamous Cell Carcinoma Trial in Canada, United States (INT230-6, anti-PD-1 antibody,
Active, not recruiting
- Breast Cancer
- +10 more
- INT230-6
- +2 more
-
Los Angeles, California
- +7 more
Jun 21, 2022
Advanced Malignant Tumors Trial in Shanghai (AK104, AK117, Capecitabine tablets)
Recruiting
- Advanced Malignant Tumors
- AK104
- +8 more
-
Shanghai, ChinaShanghai Renji Hospital
Aug 9, 2022
Metastatic Carcinoma in the Liver, Resectable Mass, Stage IV Colorectal Cancer AJCC v7 Trial in Houston (biological, other,
Completed
- Metastatic Carcinoma in the Liver
- +4 more
- Durvalumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jan 30, 2023
Advanced Lung Carcinoma, Advanced Malignant Solid Tumor, Malignant Adrenal Gland Tumor Trial in Houston (Anti-CTLA4 Monoclonal
Recruiting
- Advanced Lung Carcinoma
- +16 more
- Anti-CTLA4 Monoclonal Antibody BMS-986218
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 20, 2022